MDxHealth’s Strategic Pivot Post-ExoDx Acquisition Fuels 16% YOY Revenue Growth Amid Q2 2026 Results

DATE

Thursday, Aug. 13, 2026 at 4:30 p.m. ET

CALL PARTICIPANTS

• Chief Executive Officer – Michael McGarrity
• Interim Chief Financial Officer – Ron Kalfus

TAKEAWAYS

• Revenue — $27.2 million, up 16% YoY driven by growth in the core prostate cancer diagnostics franchise
• Gross Profit — $17.9 million (+11% YoY)
• Operating Loss — $5.1 million vs. $1.5 million loss in Q2 2025 (ExoDx integration costs)
• Pro Forma Cash Balance — $39.2 million following $20 million registered direct placement at $0.454/share
• Tissue Test Decline — 73% revenue share (vs. 96% YoY) with sequential resurgence to +1,400 tests

In a pivotal earnings call, CEO Michael McGarrity announced MDxHealth SA (NASDAQ:MDXH) successfully exited its Resolve UTI business operations by June 30, 2026, eliminating $10.4 million contingent liability while refocusing on prostate cancer diagnostics. The company reported record sequential revenue growth of 14% ($3.3 million) despite maintaining a structural YOY decline due to the discontinued Resolve business.

SUMMARY

Management reported transformative progress following Q2 2026 financial results. Key developments include:

• Operational turnaround enabling expected return to adjusted EBITDA profitability by year-end
• Strategic reallocation of 100% sales force to prostate cancer diagnostics after Resolve divestiture
• $2.1 million loss from discontinued operations reflecting Resolve exit

“Our singular focus on the urology market has unlocked unprecedented growth potential,” stated McGarrity. “The sequential tissue test acceleration validates our restructuring success despite historical business comparisons impacted by the Resolve discontinuation.”

Clinical and Strategic Developments

• Tissue Pathology Partnerships: GDP ProMPT publication strengthens market position as pathology partners reduce tissue requirements by 60% vs. competitors
• AI Initiatives: Platform development targeting 2027 implementation for patient cohort classification
• Oxford ProtecT Study: Management confirmed clear visibility with anticipated NCCN level 1 evidence validation stretching through 2027

RISKS

• Third-quarter seasonality in urology clinician patient flow patterns
  
  

  Also Read

  • NurExone Secures C$1.07 Million Through Private Placement to Advance Exosome Therapy Development
  • Venue Dispute Heats Up as Fury and Joshua Target Late 2026 Showdown
  • Pakistani Mountaineer Asma Mushtaq Dies While Descending Spantik
  • British rapper Yung Filly to face retrial on rape charges in Australia

  Source link